Isleworth (NASDAQ:ISLE) announced this afternoon that it will not complete a business combination by its initial deadline of September 1, and will instead redeem all shares.
The SPAC will cease all operations on August 29, and shareholders are expected to receive shortly thereafter $10.01 per share. As a result of the liquidation, Isleworth has also cancelled its special meeting of shareholders to extend its deadline that was previously scheduled for tomorrow, August 26.
The move comes several weeks after the SPAC mutually terminated its combination agreement with biopharmaceutical company Cytovia on June 30. Although Isleworth kept the details on the termination to a minimum, it is likely the parties decided to terminate for the same reason a number of other SPACs recently have, which pertains to the headwinds in the SPAC market as well as volatility within the general market. The termination was effective immediately, but Isleworth stated at that time that it was, “currently assessing whether it should extend its life”.
Isleworth Healthcare, which priced an upsized $180 million IPO last year in February 2021, intended to find a revenue generating US healthcare company with direct-to-patient initiatives.
The healthcare-focused SPAC marks the 19th SPAC liquidation in 2022, and the 6th in August thus far. Isleworth was led by Chairman Allen Weiss and CEO Robert Whitehead alongside CFO and EVP Dan Halvorson. The SPAC initially announced its $367 million combination with Cytovia earlier this year on April 27.
Terms Tracker for the Week Ending January 27, 2022 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. We’re coming up on the end of January, the first month of the year, and to-date no new S-1s have been filed. Additionally, the number...
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Latest SPAC News: Circle spokesperson denies blaming SEC for failed deal, BuzzFeed CEO says AI-powered content will be part of core business, and FaZe Clan faces possible delisting Circle Spokesperson Denies Blaming SEC for Failed $9 Billion Deal...
Health Sciences 2 (NASDAQ:HSAQ) announced that it closed its combination with Orchestra BioMed on January 26. HSAQ ahead of its vote pre-announced redemption figures of 1,597,888 shares equating to 67.7% redemptions, however, that’s still subject to change. However, today it was noted that Orchestra BioMed is to receive $70 million in gross proceeds including $20...
Carbon capture technology has long been talked about, and it is finally in operation with LanzaTech among the pioneers. Its plants are turning potential emissions into clothing, household goods and sustainable fuels. SPAC cash is now also an accelerant in this new process as the company announced a $1.7 billion combination with AMCI II last March. This week, we caught up with...
In this series we’ll be examining successful SPAC deals from the past both in the terms and circumstances of their de-SPAC processes and how they have weathered the storms that have followed after their public listings with research from SPACInsider contributor Anthony Sozzi. Thirty months does not sound like that long, but it’s been a...